Dendreon Corp. (Nasdaq: DNDN) reported positive results for its prostate cancer drug treatment Provenge in the reduction of deaths. Shares of the biotechnology company leaped $2.57 to $7.77.
Dendreon Reports Positive Results
October 06, 2008 at 14:20 PM EDT
